DK1695965T3 - Krystallinsk betaform af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famceutiske sammensætninger indeholdende denne - Google Patents

Krystallinsk betaform af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famceutiske sammensætninger indeholdende denne

Info

Publication number: DK1695965T3
Authority: DK; Denmark
Prior art keywords: famceutic; preparation; compositions containing; beta form; ivabradine hydrochloride
Prior art date: 2005-02-28

Application number

DK06290326T

Other languages

Danish (da)

English (en)

Inventor

Stephane Horvath

Gerard Damien

Marie-Noelle Auguste

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-28

Filing date

2006-02-28

Publication date

2008-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1695965(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-02-28 Application filed by Servier Lab filed Critical Servier Lab

2008-12-15 Application granted granted Critical

2008-12-15 Publication of DK1695965T3 publication Critical patent/DK1695965T3/da

Links

229960000504 ivabradine hydrochloride Drugs 0.000 title 1
HLUKNZUABFFNQS-ZMBIFBSDSA-N ivabradine hydrochloride Chemical compound Cl.C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 HLUKNZUABFFNQS-ZMBIFBSDSA-N 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H27/00—Special paper not otherwise provided for, e.g. made by multi-step processes
- D21H27/10—Packing paper
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
- B65D85/30—Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H21/00—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties
- D21H21/14—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties characterised by function or properties in or on the paper
- D21H21/16—Sizing or water-repelling agents
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H27/00—Special paper not otherwise provided for, e.g. made by multi-step processes
- D21H27/30—Multi-ply
- D21H27/40—Multi-ply at least one of the sheets being non-planar, e.g. crêped

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Mechanical Engineering (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Analysing Materials By The Use Of Radiation (AREA)
Plural Heterocyclic Compounds (AREA)

DK06290326T 2005-02-28 2006-02-28 Krystallinsk betaform af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famceutiske sammensætninger indeholdende denne DK1695965T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0501985A FR2882553B1 (fr)	2005-02-28	2005-02-28	Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number	Publication Date
DK1695965T3 true DK1695965T3 (da)	2008-12-15

Family

ID=34954954

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06290326T DK1695965T3 (da)	2005-02-28	2006-02-28	Krystallinsk betaform af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famceutiske sammensætninger indeholdende denne

Country Status (42)

Country	Link
US (3)	US7361649B2 (de)
EP (1)	EP1695965B9 (de)
JP (1)	JP4625776B2 (de)
KR (1)	KR100827502B1 (de)
CN (1)	CN1827600B (de)
AP (1)	AP1907A (de)
AR (1)	AR053147A1 (de)
AT (1)	ATE407926T1 (de)
BR (1)	BRPI0600623A (de)
CA (1)	CA2537414C (de)
CO (1)	CO5770096A1 (de)
CR (1)	CR8248A (de)
CU (1)	CU23614B7 (de)
CY (1)	CY1109072T1 (de)
DE (1)	DE602006002624D1 (de)
DK (1)	DK1695965T3 (de)
EA (1)	EA008464B1 (de)
EC (2)	ECSP066373A (de)
ES (1)	ES2313581T3 (de)
FR (1)	FR2882553B1 (de)
GE (1)	GEP20084465B (de)
GT (1)	GT200600084A (de)
HR (1)	HRP20080520T3 (de)
IL (1)	IL173957A0 (de)
JO (1)	JO2548B1 (de)
MA (1)	MA28131A1 (de)
ME (1)	ME01408B (de)
MY (1)	MY158128A (de)
NO (1)	NO338370B1 (de)
NZ (1)	NZ545576A (de)
PE (1)	PE20061009A1 (de)
PL (1)	PL1695965T3 (de)
PT (1)	PT1695965E (de)
RS (1)	RS50661B (de)
SA (1)	SA06270038B1 (de)
SG (1)	SG125228A1 (de)
SI (1)	SI1695965T1 (de)
TW (1)	TWI314144B (de)
UA (1)	UA80904C2 (de)
UY (1)	UY29405A1 (de)
WO (1)	WO2006092493A1 (de)
ZA (1)	ZA200601762B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2868777B1 (fr) *	2004-04-13	2006-05-26	Servier Lab	Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) *	2005-10-11	2007-12-28	Servier Lab	Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) *	2005-10-11	2007-12-28	Servier Lab	Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) *	2005-12-21	2010-12-03	Servier Lab	Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (de)	2006-11-30	2012-02-08	Cadila Healthcare Limited	Verfahren zur Herstellung von Ivabradinhydrochlorid
FR2911279B1 (fr) *	2007-01-11	2009-03-06	Servier Lab	Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
CN101353325B (zh) *	2007-07-27	2011-11-09	上海优拓医药科技有限公司	稳定型盐酸伊伐布雷定结晶及其制备方法
ES2528026T3 (es)	2007-05-30	2015-02-03	Ind-Swift Laboratories Limited	Sales de oxalato de ivabridina cristalino y polimorfos de los mismos
FR2938194B1 (fr) *	2008-11-07	2012-08-31	Servier Lab	Utilisation de l'ivabradine comme agent de diagnostic dans la methode d'angiographie coronaire par tomodensitometrie multicoupe
ES2402765T3 (es)	2008-12-22	2013-05-08	Krka, D.D., Novo Mesto	Procedimiento de preparación de ivabradina
CN101774969B (zh) *	2009-01-13	2012-07-04	江苏恒瑞医药股份有限公司	硫酸伊伐布雷定及其i型结晶的制备方法
PL2902384T3 (pl)	2010-02-12	2018-04-30	Krka, D.D., Novo Mesto	Postać chlorowodorku iwabradyny
HUP1000245A2 (en)	2010-05-07	2011-11-28	Richter Gedeon Nyrt	Industrial process for the production ivabradin salts
TWI499587B (zh) *	2010-06-03	2015-09-11	Jiangsu Hengrui Medicine Co	硫酸伊伐佈雷定及其ｉ型結晶的製備方法
US8900605B2 (en)	2010-06-14	2014-12-02	Ratiopharm Gmbh	Solid ivabradine-containing composition
WO2012025940A1 (en)	2010-08-25	2012-03-01	Cadila Healthcare Limited	Polymorphic form of ivabradine hydrochloride and process for preparation thereof
CN102304088B (zh) *	2011-07-07	2013-06-19	石药集团欧意药业有限公司	一种伊伐布雷定化合物、制备方法及其药物组合物
WO2013017582A1 (en)	2011-08-02	2013-02-07	Sandoz Ag	Acetone solvate of ivabradine hydrochloride
EP2589594A1 (de)	2011-11-04	2013-05-08	Urquima S.A.	Ivabradin-Hydrochloridform IV
EP2773621B1 (de)	2011-11-04	2015-12-30	Synthon BV	Verfahren zur herstellung einer kristallinen delta-form von ivabradinhydrochlorid
WO2013102919A1 (en)	2011-11-14	2013-07-11	Cadila Healthcare Limited	Polymorphic forms of ivabradine hydrochloride
WO2014080259A1 (en) *	2012-11-21	2014-05-30	Enaltec Labs Pvt. Ltd.	Novel polymorphic forms of alcaftadine
WO2014114341A1 (en)	2013-01-24	2014-07-31	Synthon Bv	Process for making ivabradine
EP2781509B2 (de)	2013-03-19	2023-06-14	Chemo Research, S.L.	Neues Polymorph von Ivabradinhydrochlorid und Verfahren zu dessen Herstellung
CZ2013767A3 (cs)	2013-10-02	2015-04-29	Zentiva, K.S.	Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
MX363389B (es)	2013-12-12	2019-03-20	Synthon Bv	Composicion farmaceutica que comprende ivabradina amorfa.
SI2774606T1 (sl)	2014-02-14	2019-05-31	Synthon B.V.	Farmacevtski sestavek, ki obsega polimorf IV ivabradin hidroklorida
CZ2014478A3 (cs)	2014-07-10	2015-09-16	Zentiva, K.S.	Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2016102423A1 (en)	2014-12-22	2016-06-30	Ratiopharm Gmbh	Composition comprising ivabradine in a dissolved form
GR1008821B (el)	2015-06-11	2016-08-01	Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων	Φαρμακευτικο σκευασμα που περιλαμβανει υδροχλωρικη ιβαμπραδινη και μεθοδος παρασκευης αυτου
CN107056706B (zh) *	2015-12-21	2020-05-05	江苏恒瑞医药股份有限公司	一种用于制备盐酸伊伐布雷定α晶型的方法
WO2017173458A1 (en) *	2016-04-01	2017-10-05	Swiderski Cyprianna	Compositions and methods targeting hcn channels for breathing therapeutics
TR201703066A2 (tr)	2017-02-28	2018-09-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282B1 (de)	2017-02-28	2025-10-01	Sanovel Ilac Sanayi ve Ticaret A.S.	Feste orale pharmazeutische zusammensetzungen von ivabradin
US20230181472A1 (en)	2018-10-30	2023-06-15	Amgen Inc.	Process of making ivabradine hydrochloride drug product
JP2023507626A (ja)	2019-12-16	2023-02-24	テナックス・セラピューティクス，インコーポレイテッド	駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
IT202000025312A1 (it)	2020-10-26	2022-04-26	Cambrex Profarmaco Milano S R L	Processi per la preparazione di polimorfi di ivabradina hcl
EP4456897A4 (de)	2021-12-31	2025-12-10	Tenax Therapeutics Inc	Orale formulierungen von levosimendan zur behandlung von pulmonaler hypertonie mit herzinsuffizienz mit konservierter auswurffraktion

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4490369A (en) *	1981-05-19	1984-12-25	Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung	Benzazepine derivatives, their pharmaceutical compositions and method of use
DE3119874A1 (de) *	1981-05-19	1982-12-09	Dr. Karl Thomae Gmbh, 7950 Biberach	"benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
AU647528B2 (en)	1990-08-29	1994-03-24	Humanetics Corporation	Treatment process for promoting weight loss employing a substituted delta5-androstene
FR2681862B1 (fr) *	1991-09-27	1993-11-12	Adir Cie	Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2818552B1 (fr)	2000-12-26	2003-02-07	Servier Lab	Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
FR2834896B1 (fr) *	2002-01-23	2004-02-27	Servier Lab	Composition pharmaceutique orodispersible d'ivabradine
FR2868777B1 (fr) *	2004-04-13	2006-05-26	Servier Lab	Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) *	2005-10-11	2007-12-28	Servier Lab	Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) *	2005-10-11	2007-12-28	Servier Lab	Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

2005
- 2005-02-28 FR FR0501985A patent/FR2882553B1/fr not_active Expired - Fee Related
2006
- 2006-02-13 MA MA28792A patent/MA28131A1/fr unknown
- 2006-02-14 JO JO200650A patent/JO2548B1/en active
- 2006-02-14 PE PE2006000169A patent/PE20061009A1/es active IP Right Grant
- 2006-02-15 EC EC2006006373A patent/ECSP066373A/es unknown
- 2006-02-15 EC EC2006006375A patent/ECSP066375A/es unknown
- 2006-02-21 SG SG200601133A patent/SG125228A1/en unknown
- 2006-02-21 CR CR8248A patent/CR8248A/es unknown
- 2006-02-22 AP AP2006003519A patent/AP1907A/xx active
- 2006-02-22 US US11/358,954 patent/US7361649B2/en not_active Expired - Lifetime
- 2006-02-22 CU CU20060039A patent/CU23614B7/es active IP Right Grant
- 2006-02-22 TW TW095105987A patent/TWI314144B/zh active
- 2006-02-22 GT GT200600084A patent/GT200600084A/es unknown
- 2006-02-23 BR BRPI0600623-0A patent/BRPI0600623A/pt not_active Application Discontinuation
- 2006-02-24 CA CA2537414A patent/CA2537414C/fr not_active Expired - Lifetime
- 2006-02-24 UY UY29405A patent/UY29405A1/es not_active Application Discontinuation
- 2006-02-27 KR KR1020060018722A patent/KR100827502B1/ko not_active Expired - Lifetime
- 2006-02-27 UA UAA200602129A patent/UA80904C2/uk unknown
- 2006-02-27 NZ NZ545576A patent/NZ545576A/en not_active IP Right Cessation
- 2006-02-27 EA EA200600322A patent/EA008464B1/ru unknown
- 2006-02-27 SA SA06270038A patent/SA06270038B1/ar unknown
- 2006-02-27 IL IL173957A patent/IL173957A0/en active IP Right Grant
- 2006-02-27 NO NO20060946A patent/NO338370B1/no unknown
- 2006-02-27 GE GEAP20069263A patent/GEP20084465B/en unknown
- 2006-02-27 MY MYPI20060819A patent/MY158128A/en unknown
- 2006-02-28 JP JP2006051647A patent/JP4625776B2/ja not_active Expired - Lifetime
- 2006-02-28 RS RSP-2008/0551A patent/RS50661B/sr unknown
- 2006-02-28 PT PT06290326T patent/PT1695965E/pt unknown
- 2006-02-28 DE DE602006002624T patent/DE602006002624D1/de not_active Expired - Lifetime
- 2006-02-28 CO CO06019926A patent/CO5770096A1/es not_active Application Discontinuation
- 2006-02-28 CN CN2006100580765A patent/CN1827600B/zh not_active Expired - Lifetime
- 2006-02-28 AT AT06290326T patent/ATE407926T1/de active
- 2006-02-28 PL PL06290326T patent/PL1695965T3/pl unknown
- 2006-02-28 AR ARP060100728A patent/AR053147A1/es not_active Application Discontinuation
- 2006-02-28 SI SI200630111T patent/SI1695965T1/sl unknown
- 2006-02-28 ES ES06290326T patent/ES2313581T3/es not_active Expired - Lifetime
- 2006-02-28 DK DK06290326T patent/DK1695965T3/da active
- 2006-02-28 WO PCT/FR2006/000444 patent/WO2006092493A1/fr not_active Ceased
- 2006-02-28 ZA ZA200601762A patent/ZA200601762B/xx unknown
- 2006-02-28 ME MEP-2008-551A patent/ME01408B/de unknown
- 2006-02-28 EP EP06290326A patent/EP1695965B9/de not_active Expired - Lifetime
2008
- 2008-02-26 US US12/072,461 patent/US20080161285A1/en not_active Abandoned
- 2008-09-30 CY CY20081101080T patent/CY1109072T1/el unknown
- 2008-11-27 HR HR20080520T patent/HRP20080520T3/xx unknown
2009
- 2009-10-21 US US12/589,283 patent/US7879842B2/en active Active

Also Published As

Publication number	Publication date
AP2006003519A0 (en)	2006-02-28
KR20060095501A (ko)	2006-08-31
JP2006241154A (ja)	2006-09-14
TW200640873A (en)	2006-12-01
KR100827502B1 (ko)	2008-05-06
JP4625776B2 (ja)	2011-02-02
US20080161285A1 (en)	2008-07-03
AU2006200856A1 (en)	2010-01-28
FR2882553A1 (fr)	2006-09-01
SG125228A1 (en)	2006-09-29
ECSP066373A (es)	2006-10-17
ZA200601762B (en)	2007-04-25
FR2882553B1 (fr)	2007-05-04
UY29405A1 (es)	2006-07-31
US7879842B2 (en)	2011-02-01
EP1695965B9 (de)	2009-03-04
NZ545576A (en)	2007-01-26
ATE407926T1 (de)	2008-09-15
HRP20080520T3 (en)	2009-01-31
US20060194962A1 (en)	2006-08-31
PL1695965T3 (pl)	2009-01-30
MA28131A1 (fr)	2006-09-01
CO5770096A1 (es)	2007-06-29
AR053147A1 (es)	2007-04-25
RS50661B (sr)	2010-06-30
WO2006092493A1 (fr)	2006-09-08
US20100041640A1 (en)	2010-02-18
BRPI0600623A (pt)	2006-10-24
CA2537414C (fr)	2010-02-16
CY1109072T1 (el)	2014-07-02
CU20060039A7 (es)	2008-06-30
SI1695965T1 (sl)	2009-02-28
PT1695965E (pt)	2008-10-08
ECSP066375A (es)	2006-11-16
IL173957A0 (en)	2006-07-05
CN1827600B (zh)	2010-08-11
MY158128A (en)	2016-08-30
CR8248A (es)	2008-10-06
AP1907A (en)	2008-10-23
CN1827600A (zh)	2006-09-06
SA06270038B1 (ar)	2010-03-29
NO20060946L (no)	2006-08-29
UA80904C2 (en)	2007-11-12
CA2537414A1 (fr)	2006-08-28
TWI314144B (en)	2009-09-01
HK1096387A1 (en)	2007-06-01
ME01408B (de)	2010-06-30
GEP20084465B (en)	2008-08-25
EP1695965A1 (de)	2006-08-30
US7361649B2 (en)	2008-04-22
CU23614B7 (es)	2011-01-27
EA200600322A1 (ru)	2006-08-25
DE602006002624D1 (de)	2008-10-23
PE20061009A1 (es)	2006-11-18
ES2313581T3 (es)	2009-03-01
EA008464B1 (ru)	2007-06-29
GT200600084A (es)	2006-11-22
JO2548B1 (en)	2010-09-05
EP1695965B1 (de)	2008-09-10
NO338370B1 (no)	2016-08-15

Publication	Publication Date	Title
DK1695710T3 (da)	2008-09-22	Krystallinsk betad-form af ivabradinhydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
DK1695709T3 (da)	2008-09-29	Krystalinsk gammad-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
DK1707562T3 (da)	2008-10-13	Krystallinsk v-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famaceutiske sammensætninger, som indeholder denne
DK1752443T3 (da)	2012-10-22	Ny krystallinsk form V af agomelatin, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende dette
DK1858342T3 (da)	2009-08-24	Fremgangsmåde til fremstilling af ernæringssammensætninger
SI1695965T1 (sl)	2009-02-28	Beta kristalna oblika ivabradin-hidroklorida in farmacevtski sestavki, ki jo vsebujejo
DK1893586T3 (da)	2009-01-05	Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK1828164T3 (da)	2008-12-08	Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da)	2013-09-30	Fremgangsmåde til fremstilling af dihydropteridion
ZA200703277B (en)	2008-06-25	Novel pyrimidine compounds, process for their preparation and compositions containing them
DK2431359T3 (da)	2020-07-27	Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2036892T3 (da)	2010-06-07	1,2,4,5-tetrahydro-3H-benzazepinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
PL2210872T3 (pl)	2017-07-31	Nowa postać krystaliczna III agomelatyny, sposób jej wytwarzania i kompozycje farmaceutyczne ją zawierające
DK1813678T3 (da)	2014-08-11	Fremgangsmåde til fremstilling af glycogen
DK1890996T3 (da)	2013-05-13	Krystallinske faste former af tigecyclin og fremgangsmåder til fremstilling af dette
EP1938842A4 (de)	2013-01-09	Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit verbesserten zerfallseigenschaften
DK2125788T3 (da)	2011-07-11	Heterocykliske forbindelser, sammensætninger indeholdende dem og fremgangsmåder til deres anvendelse
DK1917253T3 (da)	2015-03-30	Fremgangsmåde til fremstilling af betamimetika
DK1756049T3 (da)	2008-02-25	Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK2402306T3 (da)	2014-06-30	Fremgangsmåde til fremstilling af 5-aminolaevulinsyrehydrochlorid
DK1963251T3 (da)	2012-11-26	Fremgangsmåde til fremstilling af aminer
DK1831223T3 (da)	2013-06-10	Fremgangsmåde til fremstilling af L-biopterin
DK1692137T3 (da)	2007-04-30	Fremgangsmåde til fremstilling af tubulinininhibitorer
DK1856035T3 (da)	2009-03-09	Fremgangsmåde til fremstilling af beskyttelse amidiner
DK1912961T3 (da)	2013-02-11	Fremgangsmåde til fremstilling af bepromolin